Soleno Therapeutics (SLNO) Receivables (2013 - 2026)

Soleno Therapeutics (SLNO) posted quarterly Receivables of $47.1 million for Q1 2026, up 67.11% quarter-over-quarter from $28.2 million in Q4 2025.

Soleno Therapeutics (SLNO) Receivables (2013 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has reported Receivables for 8 consecutive years, with $47.1 million the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $47.1 million; the TTM figure through Mar 2026 stood at $47.1 million (changed N/A YoY), while the FY2025 annual figure was $28.2 million, changed N/A from the prior year.
Receivables rose to $47.1 million in Q1 2026 per SLNO's latest filing, from $28.2 million in the prior quarter.
Across five years, Receivables topped out at $47.1 million in Q1 2026 and bottomed at $24.6 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Soleno Therapeutics	2.74 Bn	2.49 Bn	93.41 Mn	47.14 Mn

Download Data